Wednesday, October 11, 2023

MIT and Dana-Farber's Breakthrough in Identifying Cancer Origins

 

In certain cancer cases, pinpointing the exact origin of the cancer is challenging, which complicates treatment decisions. Specific cancer treatments are tailored to different cancer types, and not knowing where the cancer originated from hinders treatment options.

 

Fortunately, a collaboration between researchers at MIT and the Dana-Farber Cancer Institute has unveiled a machine-learning model, named OncoNPC, that can predict a tumor's origin by analyzing the genetic sequence of about 400 genes.

 

Upon testing, the model showcased an impressive ability to correctly identify the origins of tumors 80% of the time. For tumors where predictions were made with high confidence, the accuracy surged to about 95%. This is monumental for cases classified as cancers of unknown primary (CUP), representing 3 to 5 percent of all cancer patients.

 

Utilizing the OncoNPC model on about 900 CUP tumors revealed that it could make high-confidence predictions for 40% of them. Further validating the model's precision, the predicted cancer types corresponded with patients' survival times, aligning with known prognoses for those cancer types.

 

Additionally, the model's implementation could have reshaped treatment decisions for patients. A subset of CUP patients who received treatment congruent with the model's predictions had more favorable outcomes compared to those who received mismatched treatments.

The researchers emphasized that a significant portion of patients could benefit from existing precision treatments if the cancer's origin was identified through their model.

 

The team, funded by multiple institutions, including the National Institutes of Health, is optimistic about enhancing the model's capabilities. Incorporating other data types like radiology and pathology images aims to equip the model to offer comprehensive insights, potentially guiding optimal treatment options.

 

To view the original source, visit: MIT News  

_________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

 

 

Thursday, August 17, 2023

New MR, PET Images Analyze Alzheimer’s Biomarkers

 An anti-amyloid antibody drug that reduces amyloid beta proteins in the brain has provided a novel treatment for Alzheimer’s disease. This innovative brain imaging solution for Alzheimer’s disease management can analyze Amyloid-Related Imaging Abnormalities (ARIA), a known side-effect in patients using the anti-amyloid drug. Previously, careful monitoring and management of ARIA was crucial due to the drug’s side effects. 

An Artificial Intelligence (AI) company, Neurophet, specializes in brain diseases. Neurophet has created a new technology that examines ARIA-E (edema), generally detected by T2-FLAIR, and MRI sequence, along with ARIA-H (hemorrhages), mostly recognized by GRE or SWI. To properly observe cortical amyloid beta deposition, an amyloid-PET scan is essential. 

The AI technology developed by Neurophet predicts amyloid positivity through Magnetic Resonance (MR) images before conducting amyloid-PET scans. Since amyloid-PET scans are expensive and their use and recompense are severely restricted, the use of MR images for predicting amyloid positivity could offer a cost-effective solution in regards to clinical trials and prognosis of Alzheimer’s. 

Neurophet set the stage at the 2023 Alzheimer’s Association International Conference (AAIC) with its cutting-edge brain imaging analysis technology, which can be used in both clinical trials and Alzheimer’s disease drug prescriptions. 

AQUA software, a brain MRI analysis tool, examines brain atrophy observed in neurodegenerative diseases such as Alzheimer’s by measuring cortical amyloid beta deposition, a known causative agent of the disease. Neurophet hopes to bring the products to market side-by-side with new Alzheimer’s disease treatments. The company has invested in research and development focused on ARIA side effects. 

Jake Junkil Been, CEO of Neurophet, said, “Neurophet’s major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring, and prognosis observation of Alzheimer’s disease treatment. We are going all out to develop solutions related to Alzheimer’s disease treatment to preemptively target the high-growth Alzheimer’s disease treatment market.” 

______________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at  877-704-3838 to learn more.

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

Monday, July 10, 2023

Prostate Cancer Treatment Vastly Improved

 

Cutting-edge technology and nuclear medicine are massively improving prostate cancer treatments, especially over the past two decades. Before 2000, prostate cancer was detected through manual palpation, a Prostate-Specific Antigen (PSA) blood test, and an ultrasound. Notably, prostate cancer is not visible in ultrasounds, so urologists would have to sample random prostate areas to discover the cancer. 

In the early 2000s, prostate MRI emerged and progressed through the 2010s. This technology allowed radiologists to discover whether prostate tumors were present. 

Brett Mollard, MD, a diagnostic radiologist in Michigan, said, “They could now see and target the tumors rather than randomly sampling the prostate and hoping to biopsy the tumor. We’re actively witnessing a second revolution thanks to new imaging agents, known as radiotracers or radiopharmaceuticals, for PET.”

In 2012, Positron Emission Technology (PET) radiotracers received approval, with better ones emerging in 2016. In 2021, Prostate-Specific Membrane Antigen (PSMA) was introduced, which helped to diagnose with lightning speed compared to previous methods. 

Andres Correa, MD, assistant professor at Fox Chase Cancer Center in Philadelphia, said, “While MRI has significantly reduced the rate of negative biopsies and the diagnosis of low-risk prostate cancer, the imaging modality remains limited. Up to 50 percent of patients with prostate imaging-reporting and data system (PI-RADS) 4 and 25 percent of patients with PI-RADS 5 will have benign findings on targeted biopsy. I believe that the incorporation of PSMA agents into MRI screening will allow us to better define patients who need a prostate biopsy and further reduce the number of unnecessary prostate biopsies.” 

Avenda Health’s new AI-backed prostate cancer technology, cleared by the FDA, is emerging in Los Angeles with promising results. Using machine learning, the Unfold AI platform gives physicians the most accurate picture of prostate cancer to date. 

Wayne Brisbane, MD, assistant professor of urology at UCLA Health, said, “With a wide breadth of ablative options available, Unfold AI represents the first technology to improve tumor localization and patient selection. I am hopeful that Unfold AI will be intraprostatic staging what prostate-specific membrane antigen PET/CT has been for extraprostatic staging. Additionally, there are potential applications for surgery, radiation therapy, and patient decision-making.”

Mollard said, “Prostate cancer treatment is already at a great place, especially for local and regional disease, where five-year survival rates are already over 98 percent. Over the next 10 years, I think the focus will remain on earlier and more accurate diagnosis/detection and discovering new drugs to treat metastatic prostate cancer.”  

________________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at  877-704-3838 to learn more.

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

Wednesday, June 14, 2023

Examining Breast Cancer Screening Age

 

The Radiological Society of North America (RSNA) recently released a Statement on Screening for Breast Cancer, sparked by new recommendations from the American College of Radiology (ACR) and the United States Preventive Services Task Force (USPSTF).

The ACR and Society of Breast Imaging recommend an annual mammography screening starting at age 40, but in updated guidelines, the ACR lowered its recommended age to 25. 

Stamatia V. Destounis, MD, chair of the ACR Breast Commission and a member of the RSNA Public Information Advisors Network, said, “The ACR recommends that the patient at average risk for breast cancer gets screened with mammography starting at age 40 and yearly thereafter with no upward limit, as age should not be a factor of when a patient stops screening instead of their overall health and other comorbidities. The ACR guidelines speak specifically for the high-risk patient because of family history of breast cancer, and or dense breast tissue as these are groups that the USPSTF fails to recommend any supplemental screening.” 

The USPSTF recently released a statement suggesting biennial mammography screenings for women ages 40 to 74. The recommendation states that the “current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years of age or older.” Public comments on the statement are being accepted until June 6, 2023. 

Dr. Destounis said, “The new Breast Cancer Screening Guidelines from USPSTF do not go far enough in their recommendation for breast cancer screening. Black women are 42 percent more likely to die of breast cancer in comparison to white women and the USPSTF guidelines could exacerbate the disparities by allowing cancers in those high-risk women another year to advance.”

Breast cancer screening targets small cancers in their early stages before it’s symptomatic or significantly spread throughout the body. According to 2015 National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) data, the breast cancer death rate in the United States (which remained unchanged for the previous 50 years) has decreased by 43 percent due to early mammography screening. 

_____________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at  877-704-3838 to learn more.

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/